Anti-Hypertensive Drugs - Serbia

Serbia

In Serbia, the revenue in the market of Anti-Hypertensive Drugs market is estimated to reach US$8.54m by the year 2024.
It is anticipated that there will be a steady annual growth rate of 0.19% from 2024 to 2029, leading to a market volume of US$8.62m by the end of 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Serbia has witnessed a steady increase in the demand for anti-hypertensive drugs, reflecting the growing prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Serbia has been experiencing significant growth in recent years, reflecting the increasing prevalence of hypertension in the country.

Customer preferences: Serbian customers are increasingly seeking out effective and affordable treatments for hypertension, with a particular focus on medications that are easy to administer and have minimal side effects. As a result, there has been a growing demand for combination therapies that offer multiple benefits in a single dose, as well as for generic versions of established drugs that are more affordable than branded alternatives.

Trends in the market: One of the key trends in the Anti-Hypertensive Drugs market in Serbia is the increasing use of fixed-dose combination therapies, which offer greater convenience and adherence for patients. In addition, there has been a growing focus on the development of new drugs that target specific pathways in the body, such as the renin-angiotensin system, which is a key regulator of blood pressure.

Local special circumstances: Serbia has a relatively high prevalence of hypertension, with around 40% of adults over the age of 18 affected by the condition. This has led to a significant burden on the healthcare system, with hypertension-related complications such as stroke and heart disease accounting for a large proportion of hospital admissions and healthcare costs.

Underlying macroeconomic factors: The growth of the Anti-Hypertensive Drugs market in Serbia is also being driven by a number of macroeconomic factors, including increasing healthcare spending and a growing focus on preventative care. In addition, the government has implemented a number of policies aimed at improving access to healthcare services and reducing the burden of chronic diseases such as hypertension. These factors are expected to continue to drive growth in the market over the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.